MedTrace Logo

OP5-005 Using Omnipod 5 in Adults With Type 2

NCT05815342 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 343

Last updated 2025-09-29

Study results available
· View outcomes & findings →

Summary

This is a single arm, multi-center, prospective study that will evaluate the safety and efficacy of the Omnipod 5 Automated Insulin Delivery System in adults with type 2 diabetes requiring insulin therapy.

Conditions

  • Type2 Diabetes

Interventions

DEVICE

Omnipod 5 Automated Glucose Control System

The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery

Sponsors & Collaborators

  • Jaeb Center for Health Research

    collaborator OTHER

  • Insulet Corporation

    lead INDUSTRY

Principal Investigators

  • Francisco J Pasquel, MD · Emory School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-11
Primary Completion
2024-03-01
Completion
2024-03-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05815342 on ClinicalTrials.gov